Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Apnimed’s Sleep Pill Could Disrupt CPAP | Raleigh News
Apnimed’s Nasdaq debut is sparking big investor interest, with Bank of America jumping in with a “Buy” rating and a $41 price target—potentially a 60% upside. Their star drug, Oxnimbi (AD109), could revolutionize sleep apnea treatment by targeting upper airway muscles, offering a pill alternative to cumbersome CPAP machines. Positive Phase 3 results show strong efficacy, and the FDA has accepted its application with a decision expected by February 2027. While the market potential is massive, BofA flags concerns over patient tolerance and doctor adoption, citing mixed trial feedback and some…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.